Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Medicover, Audiocast, Q1'26

By Inderes4/29/2026, 7:30 AM
Medicover

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

John Stubbington
00:01 - 14:19

Morning, everybody. Welcome to our Q1 presentation. I think we've had a good first quarter. It's been a consistent and solid position. We've got good momentum going on in the business with strong organic growth of 10.3%. This is our fifth consecutive quarter of improved margins year on year, which we're delighted with. There's been a few negative headwinds that have hit us. I don't think we need to talk about that too much. I think, as a team, we've navigated that well and it shows the strength of our model. So, it's pleasing to see the position that we've come out with despite all of that, India has shown strong momentum. We expected that. We talked about that a lot in previous quarters in terms of what we've done to be able to get a bigger level of growth and more momentum as we go towards IPO. So we're very positive with that particular result in the quarter, and we fully expect it to progress as we go through coming quarters. Very robust performance in diagnostic services. Very pleased for the team. They have done an excellent job. And our fee-for-service development is increasing in all markets, which is exactly what we want to achieve. Leverage has come down to 2.9. We expected that. We talked again about that in previous quarters, so it's good to see that going in the right direction. As we move on to the right-hand side, you can see revenue 624.22 million, organic growth of 10.3%. Adjusted EBITDA 104.6. A nice increase there of 15.4% to an adjusted EBITDA margin of 16.8%. And again, an increase from 15.7% previously. So we're seeing strong momentum in terms of our operating model as we see the operational leverage drop through. As we develop the business. A pretty good cash flow. I'll let Anand talk through the mix of that, because that's got a bit of change. And as discussed before, leverage coming down. As we move on to look at the growth metrics, you can see on the left-hand side here a very consistent growth trajectory from us. Consistent quarter-on-quarter growth in line with the expectations that we have as a business. If we look at the mix, the mix is very consistent for us. We see that in the smaller part of our revenues, we're affected by the Hungary impact as we exited there. But most of our businesses are showing solid growth. And in Germany, it's the last quarter of the reform impact that is washing through. And if we look at the revenue by payer, it is again pretty consistent. We've got a bit of work still to do on the funded business. We have said that historically, it had been driven by the higher price increases that we put through, and we fully expect to see momentum coming through in coming quarters. But what's really pleasing is that you see a very strong growth in our fee for service element, which is a reflection of how the business has changed over the years. We have a much higher exposure to this particular area of the market, and we're growing well and growing strongly, which puts us in a good place. If you look at it from a Healthcare Services perspective, again, pretty strong growth from an organic perspective. Organic growth was 11.88%; India's growth was 14.3%. But in local currency, 34.4%, which again shows the work that we've done in terms of recruiting doctors and working on our average revenue per occupied bed. Sport and wellness is going very well. Going very strong for us, which is driving some of our operational metrics; members, as I say at the moment, are pretty subdued, but we expect that to change. And more importantly, overall, due to the fact that we've got a higher fee for service mix, we're still making good momentum in terms of the relationships that we keep to be able to have long-term repeating business in this area of our business. So, revenue is good, with strong EBITA margins. You can see good increases there, driven by operational leverage. And the rest of our indicators are pretty stable from a Healthcare Services perspective as we move to Diagnostic Services. Very pleasing to see the level of growth, 9.9%, driving the revenues over 200 million, which is really, really good. The fee for service revenue increased across all markets. Again, that's been a trend that's been developing for some time. So again, well done and very impressive performance from Ukraine because they had a particularly difficult quarter in terms of some aspects of the war and the impact that had on the operating model, just with things that, you know, we take for granted. But they navigated that reasonably well and exceptionally well when you consider those circumstances. So, a big thank you to them, the German team continues to develop solid momentum, navigating the reform and building the platform for the future. So all of the reform has now washed through. It will be interesting to see our development as we progress through subsequent quarters. A number of tests have increased quite nicely. Again, weather has actually impacted some of those volumes from an organic perspective. But we don't expect that to, and it certainly won't, impact us in coming quarters. And again, I think we as a team navigated that particularly well. So on the right hand side, if you look towards the revenue by country, you can see all markets have done well. All markets are seeing growth, some of them seeing extreme growth. If you move down to the EBITDA margin, we're progressing it. We're going from good to very good. And we intend to keep pushing on with our developments as we move forward. Lab tests are up quite nicely and are a very stable mix from us. So I'll hand over to Anand, who will talk you through more of the details further down in the P&L. Thank you John. Good morning everyone. As John said, despite some headwinds we had, we delivered a strong set of results in Q1 consistently. For a number of quarters now, we have delivered double-digit organic growth and margin accretion. John said five quarters of margin accretion. And we expect that to continue in the future, which is good for us in terms of revenues. Revenues of 624 million, 8% up in total, but over 10% organic growth. We said we'd be laser focused on EBIT growth as well as EBITDA growth. And you can see a good expansion in our EBIT numbers. 46.7 million in the quarter, a margin rate of 7.5%, which is up 130 basis points. And if you look at the cash EBITDAaL, as we call it, strong performance there as well. So, 67.4 million, up 20%. A margin rate at 10.8%, which is up 110 basis points year on year. So even in challenging circumstances, our model continues to work. We also delivered a good performance in EPS. Before we move on to the next slide, just one thing to note. So the margin accretion year on year is particularly strong in Q1. That won't be the same for the rest of the year, although there will still be margin rate accretion. We are anniversarying the acquisitions we made in Q2 last year, which were not in the Q1 base. So previously, we said they would be accretive and margin rate accretive. So that laps against a base from Q1 without those acquisitions. But as we acquired it in Q2 last year, it will somewhat mitigate that effect going forward. But we still expect growth, as we said. In terms of healthcare, strong performance was observed across both business units, I would say. So healthcare, up 11.8%, price up 6.8% with healthy growth in volumes, leading to margin accretion across all profit metrics. So EBITDA was 48.9 million. John mentioned a margin rate of 11.3%, which is 140 basis points year-on-year, despite the hospital's loss. So that's in line with expectations. It grew from 2.2 million to 3.8 million in the quarter. That's largely because we opened a new hospital financial district in Hyderabad. So that's expected. And we expect that to improve as the year goes on. And just to stress the point on India. As John said, 34% growth year on year in local currency and 14% in euros, again against soft comps. But needless to say, we're pleased with that result in terms of the performance of the business. In diagnostics, organic revenue growth of 7.2%, roughly 50/50 between price and volume growth. So even in a challenging quarter for the business, as John said, they did a super job, reporting EBITDA of 33.4 million and a margin rate of 16.7%, which is up 100 basis points, and EBIT also grew. In terms of the basis points, they're a lot higher year on year. So 121 higher year on year. That's predominantly due to the SIM acquisition. So the lion's share of the increase on that is as a consequence of that. In other metrics, leverage pleasingly trends down from 3.1 to 2.9. Our tax rate is in line with expectations and guidance at 28%. From a cash flow perspective, there's a bit of a timing challenge here. So we had a little bit of a benefit in Q4 and we expect to see a benefit in Q2. So it's not a structural change. It's just timing related. We'll get back to normalized levels from Q2 onwards. And that's the same with net cash flow from operating activities and free cash flow. And the other thing I'd say on this slide is obviously that continues to grow. 13.9% versus 13% at year end and 8.3% a year ago. In terms of CapEx spend. We spent 26 million in the quarter, roughly 4% of spend. We have said before that we'd spend between 6 and 7% this year. So we'll stand by that. Although we say expansion, that happens later in the year. With regards to investment in gyms, etc. . But that will flow through in terms of the CapEx. Broadly speaking, it's roughly two-thirds on healthcare and one-third on diagnostics, with 58% on growth and the balance on maintenance. Again, as we expand into new sites, it will get back to a normalized split of about two-thirds on growth and a third on maintenance. And the final thing I'd say on this slide is actually from a medical perspective, we grew to over 1,000,000 members now. So at the end of last year. We did. We were just under a million. So we added on 110,000 m², and now we're over a million. And then finally, from me, a reminder of the midterm targets that we gave in February. So we said that our organic revenue would exceed 3.25 billion. We said our adjusted organic EBITDA would exceed 600 million. Our leverage would be below three, and our adjusted EBITDA in excess of 4.3 billion and EBIT in excess of 290 million in 2028. One quarter in, we are pleased with our progress and are in line to achieve those targets. Back to you, John. Thank you. So, in summary, we've had a solid performance with good double-digit growth and margin expansion. There's been a few challenges in the quarter, but we've navigated those particularly well. And they're not the kind of things that tend to repeat, so that will be good for us. Really good progress from a Fee-for-Service perspective. We're developing the business well in both divisions through our customer relationships; it's very important to form these relationships, and even more important to ensure they result in repeat business. And that's contributing to our growth and our improved results. So it's good to see India. India is always a good subject for us to talk about. People have been expecting us to accelerate the growth. We've been saying that we need to do that in order to keep on track from an IPO perspective. So it's pleasing to see some of those numbers coming through in local currency, which is great. And we will continue to focus on building the business, looking for growth, but at the same time, ensuring that we're efficient, improving our capacity and making sure that we balance our positions when it comes to price, cost, and particularly value for customers. So, Q1 has been good for us. It has had its challenges, but I think we're excited and energized by the model because it's weathered the storm, and we have a plan and other opportunities ahead, which I think is really, really good. So we're looking forward to taking your questions.

Operator
14:23 - 14:41

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Philip Ekengren from AB C. Please go ahead.

Philip Ekengren
14:43 - 15:06

Yes. Good morning. So first, and I'm sorry if I missed this during the call, the line has been lagging a bit, but the first two months were affected by severe weather across key regions, at least in Central and Eastern Europe, before normalising in March. At least on my sort of numbers, can you give us a sense of the magnitude of the weather drag here? Thanks.

John Stubbington
15:07 - 16:30

Yes, a few percent on our revenue growth, the lag impact. So, as you point out, January was affected. February was particularly affected. As we got to the back end of February, the sun came out again, and things kind of stabilized and consumer behavior stabilized. And as you can see from the figures that we're presenting today, that's flowed through into our March position, and therefore the overall quarter looks good. And I think that's an indication of the strength of our model. At the same time, when you look at these numbers, just bear in mind, as Anand said, that the acquisitions that we made last year, this is the final quarter for them flowing through, and they were particularly strong for us. So they have improved our margins as well. And I make one more comment just to help people with modeling, etc. , that, as we go forward in future quarters, we've got a little bit more expansion in terms of the number of facilities that will come through. It doesn't mean to say that we won't make progress from an operating model perspective. We still think we will, but there will be more of that new space so that we not only grow in 2026, but we continue to grow in 27 and beyond.

Philip Ekengren
16:32 - 16:53

Got it. Thanks. That's helpful. And then on India, I think we're all happy to see that it performs well. You talked about 34% growth in local currency. Could you elaborate a bit on the operational progress you're making down in India? and and a bit more color on, on, on how recruitment is going and how you know, everything around it.

John Stubbington
16:54 - 18:29

We know India is a really fierce market. We know it's fierce from a recruitment perspective. So, we've focused very much on getting our recruitment right and getting our replacement recruitment right. If we need to adapt to any developments, we're expanding at a fast rate. We've opened the final hospital in this round, but that still means we've not only opened hospitals, but we've still got space in the existing facilities as well that we can expand into. So, our focus is very much on making sure that we've got the right doctors who drive up utilization. And also at the same time, we need to impact the revenue per occupied bed. Obviously, that's done by the types of doctors that you recruit and the mix of their specialisms and what the types of things that they perform. So, at a micro level by each hospital, we're dealing with all of those issues. And that's why we believe we've got good momentum at the moment. And we all know that for us to continue with the ambitions that we have, that momentum has to continue for IPO to be on track. People are going to ask me today, where are we with the IPO? And the answer is going to be, we're still on Plan A. There's nobody in our business talking about plan B. We're fully aware that the external world around us has changed a bit. But from our perspective, in terms of the preparations, it makes sense for us to continue with Plan A. And that's currently the position.

Philip Ekengren
18:31 - 18:52

Thank you very much, John. I think you answered my follow up there. With the IPO process. But then perhaps the final one for me before I get back into the queue. It's been just over a year since the German pricing reform. Can you draw any conclusions from it now? Have you started to see any consolidation on the market or any change in the behavior of competitors, please?

John Stubbington
18:52 - 19:54

It's it's you know, the reform impact on us was quite tough. So I think the team has done an incredible job managing that and for us to come through as we have, as the market is seeing early signs of changes in behavior, with some of the smaller suppliers not being able to adjust and consumers adjusting, and you will note in some of the commentary that we are seeing a trend of more Fee-for-Service starting to appear in Germany. As I've said before, I don't expect that to be a waterfall and to change the market dynamics overnight. Because of the reforms that are coming, it looks like that kind of paying trend is going to continue. So, we've still got a watching brief. We've got strong pipelines when it comes to M&A in many different areas. And Germany will be no different. We've got a watching brief.

Philip Ekengren
19:55 - 19:58

Thank you very much. That was all for me. I'll give it back to the Q.

John Stubbington
19:59 - 19:59

Thanks.

Operator
20:02 - 20:06

The next question comes from Matthias from SEB. Please go ahead.

Matthias
20:09 - 20:27

Good morning. I have a couple of questions. So first one, just to be clear, when you say consumer behavior was affected, can you elaborate a little bit on what services are referred to in such a comment? So what services are affected?

John Stubbington
20:28 - 22:06

I think it was a general trend that occurred. It's been ten years since we've had the weather conditions that we had in Poland, which lasted a number of weeks. And I don't think the public were quite as used to it as they had been in history. It wouldn't have affected them ten years ago. It would have just been normal. So, people kind of worked from home, stayed away. You could see, if we looked at our telemedicine mix in our funded business, that it started to kick up, which was an indication of people not wanting to really go out and travel around. So it just subdued overall volumes for a period of time. You had a few days in Romania with severe snow. And when you get that, doctors can't get into work on time; therefore, they can't perform their procedures. You had big power outages and some blackouts in Berlin, which didn't particularly help. And all the problems in Ukraine, all of those things were just very unusual. You know, we're not sitting here and saying that that's an excuse for us. What you've seen really through the quarter, and what we take as very positive news, is that these things hit us. But we recovered as we went through the quarter. And I think that's just a sign of our model being strong, our relationships being strong, and our ability to bounce back when these things hit us. But January, February were tougher months than normal for this time of year.

Matthias
22:10 - 22:42

Okay, good. And I agree, the next question relates to Poland, of course, it's been a major driver of beating expectations for long in this company. So I think it's a little lower growth rate than you've attributed to many of the drivers. But aside from that, would you say that your sort of business momentum in Poland is intact, so to speak, and that we can climb back to higher growth rates already from Q2 there? Yeah.

John Stubbington
22:42 - 23:36

Yeah. I think it's a good observation that you make that we did point out a couple of quarters ago that even before the things we just talked about, there was an underlying trend that we needed to sort out, and Q1 doesn't help us understand whether we've sorted it or not because of the other factors that came into play. And you can see from the funded business in terms of memberships that we need to drive that higher. We're not particularly worried about it. The growth rate in Poland has been a strong base for us, and we fully expect to see momentum build in Poland as we go throughout the year. And we're looking forward to sharing that with you. So, let's see how it develops. It's not something that is causing us undue worry at this stage.

Matthias
23:39 - 23:58

Good. Last one is, firstly, sort of on Germany. What is the likely price impact on growth from here onwards? Is it neutral, or?

Anand Patel
24:01 - 24:22

Yeah. Look, I think we're expecting muted growth from a price perspective, obviously. So there have been price cuts on the cap. But as John says, what we have done is focus on our fee-for-service business in Germany, and in that regard, we've been focusing on absolute percentages and absolute numbers. But overall, it will be muted growth from a pricing perspective.

Matthias
24:25 - 24:32

Good. And the last one, you mentioned the IPO in India. So what does that mean in terms of timing?

John Stubbington
24:32 - 25:23

We have always set out the timetable, which we announced in December 2024, to be 24 months. So that's getting tight. Of course, people are going to ask questions around that. But, I think in terms of our preparations, we're on track. Yeah. And we'll push ahead exactly as we are. We've always said that we're not 100% time bound. We're in a lucky position that if circumstances, from a trading perspective, or from an external world perspective, meant a delay of a quarter or so. You know, that is still a possibility, but we are fully focused currently on Plan A, so we've been open all the way through, and it stays the same.

Matthias
25:25 - 25:27

Good. Thank you so much.

John Stubbington
25:27 - 25:28

No problem. Thank you.

Operator
25:32 - 25:37

The next question comes from Christopher Lilleberg from DAB Carnegie. Please go ahead.

Matthias
25:40 - 26:03

Thank you and good morning. I have a few questions. Maybe take them one by one. And the first one, if you could explain a little bit more the margin improvements we saw here in Q1 versus Q4. I know Q4 was a bit weaker than previous quarter, but how much of this is just seasonality versus underlying improvements, would you say?

Anand Patel
26:03 - 27:21

Yeah. So, I'll take that one. So I think I'll talk less about Q4. I'll talk more about Q1 and what it means going forward. In Q1, you've seen that I've mentioned a bit about the acquisitions versus last year when we didn't have them in our base. So that accounts for, you could argue, just over 50% of the growth that we've seen year on year in terms of margin rate. That's part one. Part two is what we have seen is fundamental improvements in volumes through all of our infrastructure. So, for example, India volumes are up 34% at a local currency level and 10% in Euro terms. You can imagine that there's margin expansion in India. In Romanian hospitals, the numbers are up year on year. We're filling those capacities and the margin rate is up there as well. So in terms of seasonality, yes. But it's hard to say. Again, as John says, because we were impacted in the first two months of the year by weather. But needless to say that the theme going forward is we're still filling our infrastructure, not just in a period where we didn't have acquisitions, but countries like India and Romania are flowing through to the numbers as well. So we still expect to see healthy margin accretion for the balance of the year.

Matthias
27:23 - 27:36

Okay. But based on previous comments, it sounds a little bit that we shouldn't expect a huge sequential margin improvements here in the next few quarters versus what you delivered in Q1. Is that correct?

Anand Patel
27:36 - 27:42

Correct. Yes. So we won't get 140 basis points growth in Q2. Yes. Correct.

Matthias
27:43 - 27:53

Okay. And could you maybe comment what the margin is in India right now and how much it has improved?

John Stubbington
27:54 - 28:19

No, we don't divulge that information. We've got to be really careful at the moment as we build towards the IPO. The Indian authorities don't like us to say too much, which doesn't help you and doesn't help our relationship with you. But we've just got to be careful. And that's not something that we divulge. And we wouldn't divulge at this stage due to the process.

Matthias
28:21 - 28:40

Okay. And I don't know if you could comment on this one, but the minority loss that you still have, I guess more or less all of that relates to India and the fact that they have financial costs in that operation as it runs right now.

Anand Patel
28:42 - 28:42

Yep.

Matthias
28:45 - 28:59

Okay. And then, on the German diagnostic margin. Is it possible to comment how that has developed since the reforms started versus what you had now in Q1?

John Stubbington
28:59 - 29:19

Again, we don't divulge that information, but as a soundbite, from our perspective, the team has handled it really, really well. And we're pleased with how they've navigated that. So I think it's a positive for us.

Matthias
29:21 - 29:27

Okay. But is it still, have you been able to keep it at least flat or is it down? Is that possible to quantify?

John Stubbington
29:28 - 29:37

I think we don't divulge, Christopher, but from my comments, it's positive for us. So I think you can read between the lines.

Matthias
29:39 - 29:58

Okay. Thanks. And then finally, sorry, a lot of questions here, but when it comes to the number of healthcare members in Poland, what will you do more precisely to increase the growth rate again? Is it just about being out selling or something else?

John Stubbington
29:58 - 31:14

I think there are a few things in there if you want a bit of flavor. One is that we made that decision about price. And when you make those decisions about price, at times you've got a bit of a lag in terms of some of the people that don't like the price. Our new business volumes are very, very good. Organic growth in the market isn't particularly strong at this moment in time. So therefore, we have to go to a different level of sophistication in terms of the different types of products that we offer to the different types of customers to stimulate more growth. We're in a good position because in our proposition, it's quite wide. So we can blend in terms of the way we do our pricing and the way that we make it more attractive for customers to cover more of their employee base. And we'll be offering different solutions in coming quarters. Related to that, we've already started, and it's getting the beginnings of some traction. That's why we're quite confident as we go forward that we should see that line start to improve again. But organic growth in the market is causing a bit of an issue that usually adjusts itself over time.

Matthias
31:16 - 31:18

Great. Thank you very much.

John Stubbington
31:18 - 31:19

No problem. Thank you.

Operator
31:23 - 31:27

The next question comes from Kane Slutzkin from Deutsche. Please go ahead.

Matthias
31:29 - 31:30

Morning, guys.

Kane Slutzkin
31:30 - 32:16

Just a quick one. Just on the Middle East situation. Obviously, you refer to it as external headwinds. I'm just wondering, is there any hedging in place to mitigate some of the potential cost inflation you might see? And how exposed are you? I would imagine there's some energy exposure, but maybe not too material, but just any comments on hedging in place to mitigate potential cost increases? And then secondly, are you comfortable with where consensus is sitting? Just trying to gauge, given some of the commentary this morning around Q1 being a bit higher and maybe there's some phasing in the numbers. I'm just wondering if you're comfortable with the consensus numbers set for the full year. Thanks.

Anand Patel
32:16 - 32:17

Sure.

John Stubbington
32:17 - 33:58

I'll answer the first one, and I'll pass the second one over to Anand. So, obviously, from a war and Middle East perspective, we have conducted exercises inside the business to understand what the impact of that would be based on what we know. So, we're putting in more monitoring positions in terms of the relationships with customers that could be more exposed. We're looking at our supply chain in terms of, are there any delays? We're looking at our building program to understand if there are impacts on that. And obviously the one that you highlighted, energy is an important factor for us. It's particularly important in Poland because there's quite a lot of property exposure there. Quite a few of our contracts from a Polish perspective on an energy basis are on a slightly longer term basis or fixed basis. And currently, of course, you'll see that the governments in many countries from an energy perspective, are putting some kind of shield or mitigating circumstances in place. So currently, there's no major impact on us, but we are taking countermeasures and we've got plans from a group perspective outlining what levers we would need to look at should circumstances change. But at the moment, as it stands today, on the 29th of April, we haven't pressed a button on those things. It's very much that we've got the watching brief with our indicators.

Anand Patel
34:00 - 34:44

Okay. From me on the consensus question. So look, we give three-year targets. So I'm not going to comment on intra-year numbers for you today. I guess the common themes of what we've said, though, are double-digit organic growth. And you can imply that from our three-year targets and margin accretion to implied rates that you can calculate for yourself in 2028. So we expect to see progress towards that. And we've said there will be a little bit slower potentially in 2026 versus an uptick in 2027-2028 towards those targets. So, for us, we've said on our call that we will achieve our targets in 2028. And after that, the year will be different.

Kane Slutzkin
34:46 - 34:57

All right. Thank you. I guess the reason I ask is, clearly you're reporting quarterly, which is pretty regularly, so it might help to have a little bit more on the near term. But yeah, take your point. Thanks.

Anand Patel
34:58 - 34:59

Thank you.

Operator
35:01 - 35:13

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Darius Saftoiu from Jefferies. Please go ahead.

Darius Saftoiu
35:16 - 35:34

Hi. Thank you for taking my questions. Two, if I may. First, in Diagnostic Services, volumes were up 9.5% in Q1, with 8.7% attributable to acquisitions. So I was wondering if you could update us on the underlying trends.

Unknown 1
35:38 - 35:43

Can you repeat that? I heard that you were talking about diagnostic volumes and underlying trends.

Darius Saftoiu
35:44 - 36:04

Yeah. Sorry. So, diagnostic volumes were up 9.5% in Q1, and 8.7% was from acquisitions. And I was wondering if you could update us on the underlying organic demand and volume growth in diagnostics in Q1. What we're struggling to.

John Stubbington
36:07 - 36:29

What we're struggling to... Apologies, but we're struggling to get the clarity of the question. So can I make a suggestion? Can you type it into the feed? Because we do want to answer your question, but we just can't pick it up. Exactly. We don't want to mislead you.

Sorry about that. I just couldn't hear it clearly.

Unknown 1
36:30 - 36:39

First, on diagnostic volumes. Test volumes were up 9.5%, with around 8.7 percentage points coming from prior year acquisition. Could you update us on how.

John Stubbington
36:40 - 37:44

I think that's one of... Sorry. We've now got the question. The test volumes are up 9.5% year on year, with around 8.7 percentage points coming from the prior year acquisitions, etc. . Yeah, I think this is just one of the areas where we were affected by some of those headwinds. It's not something we fundamentally believe we're suppressed on this particular line. You can see from the development of the Diagnostic Services segment that all our fee-for-service markets are growing quite strongly. There is a different focus in terms of the businesses looking at the higher-margin test volumes, etc. But that shouldn't affect our overall volumes as we go through. So, I wouldn't pay too much attention to that at this moment in time. Q1 was just an unusual quarter for us. We'll move past it, get to Q2. And I think that our dialogue will be slightly different than it is today.

Darius Saftoiu
37:49 - 38:26

Thank you. And I'm sorry if you don't hear me properly, I've sent the second question in the chat as well. My second question is on the regulation in Germany. I understand that the impact from last year's public reform is fully in the base now, but I was wondering if you could update us on how you assess the proposals for the private medical reform in Germany, and do you see any risks or potential opportunities for Medicover. And if the outcomes were to have less favorable impacts in certain pockets, what are the mitigation levels within your control?

John Stubbington
38:27 - 40:44

I think it's a really good question. Put it into a broader context. It's not just Germany. I think it's a lot of markets where the national funds are looking at ways that they can drive efficiency. This is nothing new. This is something that every healthcare organization, whether public or private, has to do to be able to serve their customers well. And in Germany currently, there's lots of talk about the next reform that's going to come, which is the reform that you refer to. It isn't clarified 100% yet when the date of the reform will come into effect. So, we've been planning and scenario planning and assessing the impact of this reform for some time. When it comes into effect, it's not going to affect our operations in terms of what we do simply because we're preparing for it in advance. We know that from the first reform that we needed to implement change in our business. I think I've said in previous calls that that change will last longer than any reform. So we'll continue to strengthen our operations to counterbalance any headwinds that come, but that reform, as it stands today, is quite substantial. But the last reform was, and we weathered that well. So, um, you know, we're talking theory. That theory is there; we're doing what any good business would do. We're planning for it. But as you also say, it drives opportunity. It does drive opportunity, which you can see in the German market already from what we've talked about today: there's a slight movement from people from a community that's been very used to things being paid for, to paying for themselves. So, I think that trend will start to continue. And there's a general trend in wherever you go, that people are much more interested in wellness nowadays and longevity and things along those lines. And those kind of things don't tend to be covered by the funds. So, wherever there's a challenge, there's an opportunity. And that's what Medicover has always been good at.

Darius Saftoiu
40:48 - 41:10

Yeah. Just a follow up on that. So the proposals from the association show an impact on certain diagnostic tests that could be substantial in terms of pricing. So I'm wondering how you see the mitigation factors for those that have a higher pricing impact.

John Stubbington
41:12 - 42:59

Again we can't pick up the question and I don't want to mislead. So if you can type it again, we'll come back to it. I'm sorry about that. The phone line is affecting the communication. I'm sorry. It doesn't appear that there are more questions coming through. So, there's one more question online that we will answer. When we talked about alternative products, people said, are you considering health insurance? We have health insurance solutions. So that will always be part of the mix. So, we are prepared for that from a policy perspective. There's also a question about the slowdown in diagnostic revenues in Poland and Ukraine. Um, uh, yeah. From a Poland perspective, there was a B2B contract change which would have affected our underlying numbers. We are confident that we will be able to outgrow that as we go through the year. And Ukraine was impacted by the weather because at that time of year down there, it's quite tough. But the war impacted at a higher rate in Q1. And as a consequence of that, it affected the numbers. Um, you know, that, that, uh, that seems to have recovered as we've gone through the quarter. So again, we expect that to be stronger.

Unknown 1
43:05 - 43:05

Yeah.

John Stubbington
43:06 - 43:57

There's also a question about the revenues we generate on CT and MRI scanners with the public funds in Poland above the contract limit. That's not something that we would disclose. It's too much operational detail and too sensitive. But what I would say is that we have limited exposure to the NFZ. They are making changes in their contract limits in this particular area. But it's not a big part of our business volumes. It will impact us, but at the same time, it's going to impact the speed of delivery for the consumer. So there'll probably be a change in mix that happens here from some people that historically have gone to NFZ. And over time they will switch back to being out of pocket.

Unknown 1
44:00 - 44:02

We'll go back to the queue.

John Stubbington
44:04 - 44:05

Happy to do so.

Operator
44:06 - 44:10

The next question comes from Matthias Batstone from Seb. Please go ahead.

Matthias Batstone
44:12 - 44:44

Yes. Thank you. Just a clarification. So I just wanted to make sure I catch your comments correctly. So the EBITDAaL margin improved by 90 basis points year over year in Q1. So, did I catch it correctly? The year-on-year margin improvement in coming quarters will be much more modest. So we obviously don't know exactly how it should be per quarter here. I just wanted to understand the profile for Q2 through Q4 based on the comments.

Anand Patel
44:45 - 45:16

So, obviously it's difficult for me to say without telling you the number, which I don't want to do. But if you look at. More than 50% of the growth in Q1 on the margin rate of roughly 120 basis points is due to the acquisition. So that disappears in Q2 because it's in our base. So hopefully from that, you can figure out what I'm saying with regards to the number for the rest of the year.

Matthias Batstone
45:18 - 45:21

No, absolutely. Thank you so much.

Operator
45:26 - 45:33

There are no more phone questions at this time. So I hand the conference back to the speakers for any closing comments.

John Stubbington
45:34 - 46:22

I'll just thank you to everybody for attending. There were quite a lot of varied questions today and a lot of detail that we went into, which was fully expected given the difficult first-quarter headwinds that are now gone. So, we're looking forward to progressing for the rest of the year. As I said before, we're pleased with the progress we've made in Q1. We're very pleased with the strength of our model considering those unusual circumstances, and that has energized us for the future. So we're very much looking forward to how we develop this year, and finally, a big thank you to everybody in Medicover for making these results happen. They've done a fantastic job. So thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…